Read Full Article: Cancer Intralesion Chemotheraphy with Solasodine Rhamnosyl Glycosides
Abstract: Solasodine rhamnosyl glycosides (SRGs) are a new class of chemotherapeutic agents for the treatment of cancer. SRGs in a cream formulation Curaderm BEC5 is now available for the treatment of skin cancers. Phase 2 clinical trials with intravenous (i.v.) administration of SRGs on patients with internal cancers are currently being done. The specificity and mode of action of SRGs are vastly different than those of other traditional anti-mitotic anticancer drugs. These differences have now led to SRGs intralesion chemotherapy, a very effective, new safer, anticancer modality, resulting in rapid regression of solid tumours using 1% of the dose that is required when compared with SRGs i.v. administration. In this feasibility pilot study large external tumours of animals and man were injected intralesionally with SRGs. Results demonstrate that SRGs when injected intralesionally successufully dispose of large tumours without any clinical adverse effects and that apoptosis is the cause of cancer cell death.
Keywords: Cancer, solasodine rhamnosyl glycosides, BEC, apoptosis, intralesion
Read Full Article: Cancer Intralesion Chemotheraphy with Solasodine Rhamnosyl Glycosides
Originally published in Medwell Online: Research Journal of Biological Science 3(9): 1008-1017,2008 ISSN: 1815-8846